Sight Sciences (SGHT) to Release Quarterly Earnings on Tuesday

Sight Sciences (NASDAQ:SGHTGet Rating) is scheduled to release its earnings data after the market closes on Tuesday, May 10th. Analysts expect Sight Sciences to post earnings of ($0.41) per share for the quarter. Sight Sciences has set its FY 2022 guidance at EPS.Persons interested in participating in the company’s earnings conference call can do so using this link.

Sight Sciences (NASDAQ:SGHTGet Rating) last released its quarterly earnings results on Thursday, March 24th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.39) by $0.05. On average, analysts expect Sight Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

SGHT stock opened at $7.37 on Tuesday. Sight Sciences has a 52-week low of $6.25 and a 52-week high of $42.57. The company’s 50 day simple moving average is $12.48 and its 200-day simple moving average is $16.82. The company has a debt-to-equity ratio of 0.14, a quick ratio of 20.26 and a current ratio of 20.51.

A number of research firms have recently issued reports on SGHT. Piper Sandler cut their price target on shares of Sight Sciences from $43.00 to $23.00 in a report on Friday, March 25th. Zacks Investment Research downgraded shares of Sight Sciences from a “buy” rating to a “hold” rating in a research report on Thursday, March 10th. William Blair began coverage on shares of Sight Sciences in a research report on Thursday, February 3rd. They set an “outperform” rating on the stock. Morgan Stanley raised shares of Sight Sciences from an “equal weight” rating to an “overweight” rating and lowered their price objective for the company from $36.00 to $27.00 in a research report on Friday, January 7th. Finally, Citigroup lowered their price objective on shares of Sight Sciences from $39.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, March 25th. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $29.60.

A number of hedge funds have recently bought and sold shares of SGHT. Charles Schwab Investment Management Inc. boosted its holdings in shares of Sight Sciences by 1.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 75,522 shares of the company’s stock worth $1,327,000 after buying an additional 942 shares during the period. Royal Bank of Canada bought a new stake in shares of Sight Sciences during the 3rd quarter worth $54,000. Legal & General Group Plc boosted its holdings in shares of Sight Sciences by 238.7% during the 4th quarter. Legal & General Group Plc now owns 3,756 shares of the company’s stock worth $66,000 after buying an additional 2,647 shares during the period. Morgan Stanley bought a new stake in shares of Sight Sciences during the 3rd quarter worth $69,000. Finally, California State Teachers Retirement System bought a new stake in shares of Sight Sciences during the 3rd quarter worth $137,000. 60.76% of the stock is owned by institutional investors.

Sight Sciences Company Profile (Get Rating)

Sight Sciences, Inc, an ophthalmic medical device company, engages the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology, for the treatment of dry eye disease (DED) for ophthalmologists and optometrists.

Featured Stories

Receive News & Ratings for Sight Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sight Sciences and related companies with MarketBeat.com's FREE daily email newsletter.